Screener
Xenon Pharmaceuticals XENE Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Shareholders’ equity: | ||
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 96,752,884 (December 31, 2025 - 80,010,790) (note 8) | $2,426,619 | $1,598,571 |
| Additional paid-in capital | 276,851 | 228,234 |
| Accumulated deficit | (1,458,418) | (1,245,380) |
| Accumulated other comprehensive income (loss) | (2,656) | 335 |
| Total shareholders’ equity | $1,242,396 | $581,760 |
| Total liabilities and shareholders’ equity | $1,295,772 | $633,163 |
| Commitments and contingencies (note 11) |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's total liabilities & equity?
- Xenon Pharmaceuticals (XENE) reported total liabilities & equity of $1.3B in Q2 2026.
- How has Xenon Pharmaceuticals's total liabilities & equity changed year-over-year?
- Xenon Pharmaceuticals's total liabilities & equity increased by 92.2% year-over-year, from $674.28M to $1.3B.
- What is the long-term trend for Xenon Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's total liabilities & equity has grown at a 27.3% compound annual growth rate (CAGR), from $189.19M to $633.16M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.
Ask your AI about Xenon Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude